دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 30,000,000 تومان- قیمت ویژه : 6,250,000تومان
دسترسی یکماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 31 ﺭﻭﺯ
قیمت : 3,000,000 تومان- قیمت ویژه : 1,250,000تومان
Evolutionary History of the Comorbidity-Driven Coronary Microvascular Endothelial Inflammation Hypothesis and Its Metamorphosis to the Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
doi : 10.1016/j.jchf.2025.102822
Volume 14, Issue 2, February 2026, 102822
LV Structure and Function in HFrEF With and Without Peak-Flow-Triggered Adaptive Servo-Ventilation-Treated Sleep-Disordered Breathing
doi : 10.1016/j.jchf.2025.02.016
Volume 14, Issue 2, February 2026, 102434
Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial
doi : 10.1016/j.jchf.2025.102703
Volume 14, Issue 2, February 2026, 102703
Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction
doi : 10.1016/j.jchf.2025.102712
Volume 14, Issue 2, February 2026, 102712
Inflammation and the Need for Biology-Driven Care in Heart Failure
doi : 10.1016/j.jchf.2025.102834
Volume 14, Issue 2, February 2026, 102834
Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced
doi : 10.1016/j.jchf.2025.102751
Volume 14, Issue 2, February 2026, 102751
Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Findings From EMPEROR-Preserved
doi : 10.1016/j.jchf.2025.102889
Volume 14, Issue 2, February 2026, 102889
Magnesium, SGLT2 Inhibitors, and Heart Failure: A Convoluted Story
doi : 10.1016/j.jchf.2025.102888
Volume 14, Issue 2, February 2026, 102888
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
doi : 10.1016/j.jchf.2025.03.008
Volume 14, Issue 2, February 2026, 102441
Therapeutic Sequencing in Obstructive Hypertrophic Cardiomyopathy: Seeing the Forest Through the Trees
doi : 10.1016/j.jchf.2025.102836
Volume 14, Issue 2, February 2026, 102836
Thin Evidence, Heavy Need: The Case for GLP-1 Agonist Trials Specific to Patients With HFrEF
doi : 10.1016/j.jchf.2025.102715
Volume 14, Issue 2, February 2026, 102715
Plasma Aldosterone Measurement to Guide Prevention and Treatment of Heart Failure in Black Adults With Hypertension
doi : 10.1016/j.jchf.2025.102848
Volume 14, Issue 2, February 2026, 102848
Could Mineralocorticoid Receptor Antagonists Be Harmful in Some Patients With Heart Failure?
doi : 10.1016/j.jchf.2025.102891
Volume 14, Issue 2, February 2026, 102891
HFmrEF and HFpEF: Detecting Progression Before Deterioration
doi : 10.1016/j.jchf.2025.102842
Volume 14, Issue 2, February 2026, 102842
The AHFTC Fellowship Match in an Era of Declining Interest: Which Programs Fill and Why
doi : 10.1016/j.jchf.2025.102680
Volume 14, Issue 2, February 2026, 102680
Life’s Essential 8 and Incident Heart Failure Among REGARDS Participants With and Without Diabetes
doi : 10.1016/j.jchf.2025.102686
Volume 14, Issue 2, February 2026, 102686
Clinical Implications of the P.V142I TTR Variant: Insights From CARS
doi : 10.1016/j.jchf.2025.102704
Volume 14, Issue 2, February 2026, 102704
Finerenone and Quality of Life Assessed Using the EuroQol 5-Dimension Questionnaire Level Sum Score in Patients With HFmrEF or HFpEF
doi : 10.1016/j.jchf.2025.102705
Volume 14, Issue 2, February 2026, 102705
Novel 4-Stage Classification to Estimate Right Atrial Pressure by Point-of-Care Ultrasound of Neck Vasculature
doi : 10.1016/j.jchf.2025.102707
Volume 14, Issue 2, February 2026, 102707
Surveillance Patterns for Allograft Vasculopathy in Heart Transplant Recipients in PET Myocardial Perfusion Imaging Performing Centers in the United States
doi : 10.1016/j.jchf.2025.102718
Volume 14, Issue 2, February 2026, 102718
Michael R. Bristow, MD, PhD: A Translational Pioneer Who Changed the Field of Heart Failure
doi : 10.1016/j.jchf.2026.102936
Volume 14, Issue 2, February 2026, 102936
CMR-First in Newly Diagnosed HFrEF: Specificity, Reference Standards, and the Value of Integrated Assessment
doi : 10.1016/j.jchf.2025.102827
Volume 14, Issue 2, February 2026, 102827
REPLY: CMR-First in Newly Diagnosed HFrEF: Specificity, Reference Standards, and the Value of Integrated Assessment
doi : 10.1016/j.jchf.2025.102829
Volume 14, Issue 2, February 2026, 102829
Beyond the IVC: Nephrology Perspectives on Ultrasound-Guided Decongestion in Heart Failure
doi : 10.1016/j.jchf.2025.102832
Volume 14, Issue 2, February 2026, 102832
REPLY: Beyond the IVC: Nephrology Perspectives on Ultrasound-Guided Decongestion in Heart Failure
doi : 10.1016/j.jchf.2025.102835
Volume 14, Issue 2, February 2026, 102835
Effects of GLP-1 RA Initiation in Patients With HFrEF and Implantable Cardiac Devices Divided for BMI Values
doi : 10.1016/j.jchf.2025.102839
Volume 14, Issue 2, February 2026, 102839
REPLY: Effects of GLP-1 RA Initiation in Patients With HFrEF and Implantable Cardiac Devices Divided for BMI Values
doi : 10.1016/j.jchf.2025.102837
Volume 14, Issue 2, February 2026, 102837
How to Rescue the Field of Heart Failure
doi : 10.1016/j.jchf.2025.102838
Volume 14, Issue 2, February 2026, 102838
